Galectin Therapeutics Director Arthur Greenberg Buys 1,000 Shares (GALT)
Galectin Therapeutics (NASDAQ:GALT) Director Arthur Greenberg bought 1,000 shares of Galectin Therapeutics stock in a transaction that occurred on Tuesday, August 19th. The shares were purchased at an average cost of $4.56 per share, for a total transaction of $4,560.00. Following the completion of the purchase, the director now directly owns 96,667 shares of the company’s stock, valued at approximately $440,802. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Galectin Therapeutics (NASDAQ:GALT) opened at 4.86 on Friday. Galectin Therapeutics has a 52-week low of $4.28 and a 52-week high of $19.11. The stock has a 50-day moving average of $9.15 and a 200-day moving average of $12.53. The company’s market cap is $107.1 million.
Galectin Therapeutics (NASDAQ:GALT) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.17) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.21) by $0.04. Analysts expect that Galectin Therapeutics will post $-1.03 EPS for the current fiscal year.
GALT has been the subject of a number of recent research reports. Analysts at Aegis downgraded shares of Galectin Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 1st. Separately, analysts at BMO Capital Markets reiterated a “positive” rating on shares of Galectin Therapeutics in a research note on Tuesday, July 29th. Finally, analysts at MLV & Co
cut their price target on shares of Galectin Therapeutics from $27.00 to $15.00 in a research note on Tuesday, July 29th. They now have a “buy” rating on the stock.
Galectin Therapeutics Inc (NASDAQ:GALT) is a development-stage company engaged in drug development to create new therapies for cancer and fibrotic disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.